Omega Healthcare Investors Inc
Q3 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +0.27%.
Did OHI Beat Earnings? Q3 2025 Results
Omega Healthcare Investors delivered a standout third quarter, posting earnings per share of $0.59 against a consensus estimate of $0.45, a beat of nearly 31%, while revenue of $311.59 million cleared Wall Street's $261.59 million forecast by 19.11% and climbed 12.9% from a year ago. The primary engine behind the results was a surge in rental income to $260.74 million from $227.77 million in Q3 2024, reflecting the skilled nursing REIT's aggressive investment pace, which reached $756.02 million year-to-date through September. A headline post-quarter development reinforced the growth trajectory: Omega formed a joint venture with Saber Healthcare, acquiring a 49% equity stake in 64 facilities generating $69.40 million in annual contractual rent, a deal that signals the company's expanding appetite for complex partnership structures. Adjusted FFO rose to $0.79 per diluted share from $0.74 a year ago, and management lifted full-year 2025 AFFO guidance to $3.08 to $3.10 per share, up from both the prior range of $3.04 to $3.07 and the initial outlook of $2.90 to $2.98.
- Rental income growth driven by $978 million in new investments year-to-date
- Improving operator occupancy reaching 82.6% for twelve months ended June 30, 2025
- EBITDARM coverage improvement to 1.91x before management fees
- Gain on asset sales of $28.2 million from sale of 11 facilities
- Increased real estate loan interest income to $34.4 million from $33.6 million in Q3 2024
- Higher other income of $16.8 million vs. a loss of $1.0 million in Q3 2024
“We again delivered strong quarterly results, as we continue to grow FAD per share while further de-levering the balance sheet. We have accretively invested nearly $1 billion year-to-date and, as a result, we are increasing our 2025 AFFO guidance again to now be between $3.08 and $3.10 per share, up from our initial guidance range of between $2.90 and $2.98 per share.”
Omega Healthcare Investors CEO, on the earnings call
Forward Guidance & Outlook
Omega increased its full year 2025 Adjusted FFO guidance to $3.08–$3.10 per diluted share, up from the prior range of $3.04–$3.07 and well above the initial guidance of $2.90–$2.98. The revised guidance incorporates $756 million in new investments completed year-to-date through September 2025 and the $222 million Saber JV investment. Key assumptions include: Genesis continues full contractual payments, Maplewood continues rent at $6.3 million per month, Q4 G&A expense of $13.5–$14.5 million, repayment of $245.9 million GBP secured mortgage in November 2025 via the delayed draw term loan, approximately $56 million of maturing mortgages converting to fee simple real estate with the balance extended beyond 2025, and approximately $15 million in asset sales. The guidance excludes additional acquisitions, capital markets activity, and additional credit loss provisions.
OHI YoY Financials
OHI Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.